Two decades of growth and trends in the FDA authorization of digital medical devices.

Abstract

The regulatory environment for digital medical devices has rapidly changed in recent years as policymakers have worked to keep up with the evolving landscape of biomedical technologies. Despite the need for new regulatory efforts, existing data assets in the US are not capable of systematically tracking whether FDA-authorized medical devices have digital components, limiting regulators' ability to incorporate software-specific considerations into post-market surveillance activities and limiting